CLX

Business profile & competitive position

The Clorox Company operates in the Consumer Defensive sector within the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, with fiscal 2026 net sales of $6.7 billion, roughly 9,200 employees, operations in about 25 countries, and sales in roughly 95 markets. Its consumer brands include Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while professional products are sold under Purell, CloroxPro, and Clorox Healthcare. In April 2026, Clorox completed the acquisition of GOJO Industries, expanding its health and hygiene portfolio and adding business-to-business scale.

The business model is built on recurring-use staples, which usually produces stable cash flows. That stability is reflected in a low equity beta of 0.54. However, the margin and return data tell a more nuanced story. The net margin of 8.7% is respectable for a large packaged-goods company but leaves limited room for cost shocks, while the ROE of -1,893.5% reflects negative or very low reported shareholders’ equity rather than an operational loss of that scale. Importantly, customer concentration is a structural risk: Walmart accounted for 26% of fiscal 2026 net sales, and the five largest customers represented about half of consolidated net sales. That concentration gives retailers negotiating leverage and means revenue quality depends heavily on shelf-space and pricing discipline at a handful of accounts.

Financial posture

Clorox’s current market capitalization is $13.0 billion and the stock trades at $107.17 with a P/E of 22.2 and a beta of 0.54. A P/E around 22x is typical for a defensive consumer name with recurring demand but only moderate growth expectations. The 8.7% net margin supports the staple-profitability profile, though it is not high enough to fully insulate earnings from commodity, freight, or marketing-cost swings.

The negative ROE is the most eye-catching figure. Because ROE is earnings divided by shareholders’ equity, a value near -1,900% generally signals that reported equity has been pushed deeply negative by a combination of share buybacks, accumulated deficits, and leverage, not that operating earnings have collapsed. In other words, the metric is a balance-sheet artifact more than a measure of current profitability. Investors usually pair this with cash-flow and debt metrics; the combination of a 0.54 beta and a relatively full P/E suggests the market views Clorox as a low-volatility, income-oriented name where balance-sheet structure and margin defense matter as much as top-line growth.

Strategic priorities & outlook

The company’s most recent 10-K outlines an operating agenda centered on its IGNITE strategy. The filing describes four strategic choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Near-term priorities include completing and optimizing a new enterprise resource planning system and a broader digital transformation intended to generate long-term efficiencies across supply chain, digital commerce, innovation, and brand building. Clorox also plans to invest in strong brands, strategic digital capabilities, and a streamlined operating model to build resilience and deliver consistent, profitable growth.

A separate priority is advancing health and hygiene expansion, including integrating the GOJO acquisition and growing professional and institutional markets. Operationally, fiscal 2026 saw declines in organic sales and earnings, with diluted EPS down 26%, partly because macroeconomic headwinds and ERP transition timing had pulled some sales into fiscal 2025. A notable corporate event was the January 31, 2026 expiration of the Glad bags and wraps venture with Procter & Gamble, which required Clorox to purchase P&G’s 20% interest; afterward Glad retained core intellectual property licenses on a royalty-free basis. The strategic read-through is that fiscal 2027 is likely to be a year of integration and stabilization, balancing GOJO synergies against the lingering effects of ERP disruption and pulled-forward volume.

Macro & geopolitical exposure

As a Household & Personal Products company, Clorox faces macro exposures common to the consumer-staples supply chain. Raw-material costs, including petrochemical-based resins and packaging, wood and charcoal inputs for Kingsford, and agricultural-derived ingredients for cleaners and wipes, can move with energy, freight, and commodity markets. Regulatory exposure is also material: disinfectant and personal-care claims are overseen by agencies such as the EPA and FDA, while packaging, labeling, and advertising fall under FTC and state environmental rules. Trade policy and tariffs can affect imported raw materials and packaging, and currency risk is present because the company sells in about 95 markets. Finally, the industry’s high retail concentration means pricing power is constantly tested by both powerful customers and private-label alternatives.

Recent developments

• On August 24, 2026, defenseworld.net reported that Barrow Hanley Mewhinney & Strauss LLC acquired 106,377 shares of The Clorox Company.
• On the same day, defenseworld.net reported that Bank of New York Mellon Corp made a new $123.15 million investment in Clorox.
• On August 22, 2026, defenseworld.net reported that BlackRock Inc. acquired 10,044,423 shares of CLX.
• On August 21, 2026, zacks.com published “How GOJO Could Shape Clorox’s Fiscal 2027 Growth and Margin Outlook.”

The cluster of institutional position disclosures suggests greater institutional accumulation as of the most recent filing period, though 13F-style filings capture quarter-end holdings rather than live directional trades. The Zacks article ties directly to the 10-K theme that GOJO integration and professional-market expansion are central to the fiscal 2027 margin narrative.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Clorox beat earnings estimates six times, a 75.0% beat rate, with an average earnings surprise of 9.4%. The average five-day price move after earnings across those quarters was +1.67%, classified as an upward drift. Those averages, however, mask considerable quarter-to-quarter dispersion.

The four most recent reports illustrate the pattern. On August 3, 2026, Clorox reported actual EPS of $1.66 against an estimate of $1.64, a 1.2% beat; the stock rose 6.52% the next day and 9.61% over the following five days. On April 30, 2026, the company reported $1.64 versus $1.55, a 5.8% beat, yet the stock fell 9.67% the next day and 4.49% over the next five days. On February 3, 2026, actual EPS of $1.39 missed the $1.43 estimate by 2.8%, but the stock still gained 2.43% the next day and 5.63% over five days. On November 3, 2025, actual EPS of $0.85 beat the $0.818 estimate by 3.9%; the stock rose 1.17% the next day but drifted 4.08% lower over the following five sessions.

The takeaway is that while the headline beat rate and average post-earnings drift are positive, next-day reactions do not always align with the size or direction of the earnings surprise. Clorox is scheduled to report next on November 3, 2026, after the close, with a consensus EPS estimate of $1.11. That estimate sits well below the $1.66 and $1.64 reported in the two most recent quarters, implying the market’s real expectation is for a seasonal or post-acquisition earnings step-down.